PDF herunterladen
Aktuelle Dermatologie 2015; 41(06): 234-241
DOI: 10.1055/s-0034-1392014
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Kutane und systemische Borreliose

Pathogenese – Diagnose – TherapieCutaneous and Systemic Lyme DiseasePathogenesis – Diagnosis – Treatment
T. Thuile
1   Abteilung für Dermatologie, Venerologie und Allergologie, Akademische Lehrabteilung der Medizinischen Universität Innsbruck, Zentrales Lehrkrankenhaus Bozen/Bolzano, Italien
,
K. Eisendle
1   Abteilung für Dermatologie, Venerologie und Allergologie, Akademische Lehrabteilung der Medizinischen Universität Innsbruck, Zentrales Lehrkrankenhaus Bozen/Bolzano, Italien
,
A. Tschachler
2   Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Innsbruck, Österreich
,
B. Zelger
2   Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Innsbruck, Österreich
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. April 2015 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Die Borreliose mit ihren vielgestaltigen und stadienhaften Krankheitsbildern zählt zu den häufigsten Zoonosen der nördlichen Hemisphäre. Die pathogene Spirochäte Borrelia burgdorferi gelangt über den Speichel der Schildzecken (Ixodides) in die Haut des Menschen. Eine geschickte Regulation der oberflächlichen Lipoproteine ermöglicht dem Bakterium trotz der raschen und ausgeprägten Immunreaktion in vielen Fällen eine Streuung im Körper. Bleibt die Infektion unbehandelt und/oder bei Befall entsprechend immunologisch „anfälliger“ Personen können sich nach Latenzzeiten von Wochen bis Jahren kutane oder systemische Symptome manifestieren. Borrelien persistieren bevorzugt in immunologisch privilegierten Geweben, wie dem peripheren und zentralen Nervensystem und den Gelenken. Neben den klassischen Hautmanifestationen der Borreliose, wie dem Erythema migrans, dem Borrelien-Lymphozytom oder der Acrodermatitis chronica atrophicans, konnten in den letzten 20 Jahren Borrelien auch in Hautbiopsien anderer Hauterkrankungen, wie der Morphea, des Lichen sclerosus, des Granuloma anulare, der kutanen Sarkoidose, der Necrobiosis lipoidica und bei Fällen von kutanen B-Zell-Lymphomen nachgewiesen werden. Die Rolle der Keime in der Pathogenese letzterer Krankheitsbilder bietet Raum für Forschung und Diskussionen. Die antibiotische Therapie der Borreliose richtet sich nach Stadium und Hauptmanifestation der Symptomatik.

Abstract

Lyme disease with its manifold clinical presentations accounts for one of the most common zoonoses in the northern hemisphere. The pathogen Borrelia burgdorferi penetrates human skin through saliva that ticks excrete during feeding periods. Although a strong immune response is triggered immediately, a sophisticated mechanism that affects the regulation of the superficial antigen lipoproteins, allows the bacterium to spread within the body. If not treated correctly, cutaneous or systemic symptoms can manifest after weeks to years. Borrelia preferentially persists in immunologically privileged tissues such as the peripheral and central nervous system and the joints. Besides in erythema migrans, borrelial lymphomcytoma and acrodermatitis chronica atrophicans, borrelial spriochaetes could also be detected in ‘non classical’ skin disorders, such as morphea, lichen sclerosus, grannuloma anulare, cutaneous sarcoidosis, necrobiosis lipoidica and cases of cutaneous B cell lymphoma. The role of Borrelia in the pathogenesis of these latter diseases is discussed and gives room for further research. The antibiotic treatment for cutaneous and systemic borreliosis should be chosen according to main symptoms and clinical stage.

 

  • Literatur

  • 1 Burgdorfer W, Barbour AG, Hayes SF et al. Lyme disease – a tick-borne spirochetosis?. Science 1982; 216: 1317-1319
    CrossrefPubMedSuche in Google Scholar
  • 2 Steere AC, Malawista SE, Snydman DR et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum 1977; 20: 7-17
    CrossrefPubMedSuche in Google Scholar
  • 3 Smith R, Takkinen J. Lyme borreliosis: Europe-wide coordinated surveillance and action needed?. Euro Surveill 2006; 11 E060622 1
    PubMedSuche in Google Scholar
  • 4 Wilking H, Stark K. Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009 – 2012. Ticks Tick Borne Dis 2014; 5: 219-224
    CrossrefPubMedSuche in Google Scholar
  • 5 Institut RK. Seroprävalenz der Lyme-Borreliose bei Kindern und Jugendlichen in Deutschland. Epidemiologisches Bulletin 2012; 14
    PubMedSuche in Google Scholar
  • 6 Wilking H, Fingerle V, Klier C et al. Antibodies against Borrelia burgdorferi sensu lato among Adults, Germany, 2008 – 2011. Emerg Infect Dis 2015; 21: 107-110
    CrossrefPubMedSuche in Google Scholar
  • 7 Rizzoli A, Silaghi C, Obiegala A et al. Ixodes ricinus and Its Transmitted Pathogens in Urban and Peri-Urban Areas in Europe: New Hazards and Relevance for Public Health. Front Public Health 2014; 2: 251
    PubMedSuche in Google Scholar
  • 8 Eisendle K, Deluca J, Zelger B. Borreliosis (Lyme Disease). Dermatitis – Causes, Symptoms, and Treatment Options. Nova Science Pub Inc 2013; 69-93
    PubMedSuche in Google Scholar
  • 9 Rauter C, Hartung T. Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes ricinus ticks in Europe: a metaanalysis. Appl Environ Microbiol 2005; 71: 7203-7216
    CrossrefPubMedSuche in Google Scholar
  • 10 Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest 2004; 113: 1093-1101
    CrossrefPubMedSuche in Google Scholar
  • 11 Fraser CM, Casjens S, Huang WM et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi . Nature 1997; 390 (6660): 580-586
    CrossrefPubMedSuche in Google Scholar
  • 12 Casjens S, Palmer N, van Vugt R et al. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi . Mol Microbiol 2000; 35: 490-516
    PubMedSuche in Google Scholar
  • 13 Sze CW, Zhang K, Kariu T et al. Borrelia burgdorferi needs chemotaxis to establish infection in mammals and to accomplish its enzootic cycle. Infect Immun 2012; 80: 2485-2492
    CrossrefPubMedSuche in Google Scholar
  • 14 Schwan TG, Piesman J. Temporal changes in outer surface proteins A and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J Clin Microbiol 2000; 38: 382-388
    PubMedSuche in Google Scholar
  • 15 Srivastava SY, de Silva AM. Reciprocal expression of ospA and ospC in single cells of Borrelia burgdorferi . J Bacteriol 2008; 190: 3429-3433
    CrossrefPubMedSuche in Google Scholar
  • 16 Cook MJ. Lyme borreliosis: a review of data on transmission time after tick attachment. Int J Gen Med 2015; 8: 1-8
    PubMedSuche in Google Scholar
  • 17 Lusitani D, Malawista SE, Montgomery RR. Borrelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components. J Infect Dis 2002; 185: 797-804
    CrossrefPubMedSuche in Google Scholar
  • 18 Hofmann H. [Lyme borreliosis. Cutaneous manifestation]. Hautarzt 2005; 56: 783-795 quiz 796
    CrossrefPubMedSuche in Google Scholar
  • 19 Fischer JR, LeBlanc KT, Leong JM. Fibronectin binding protein BBK32 of the Lyme disease spirochete promotes bacterial attachment to glycosaminoglycans. Infect Immun 2006; 74: 435-441
    CrossrefPubMedSuche in Google Scholar
  • 20 Hofmann H. [The variable spectrum of cutaneous Lyme borreliosis. Diagnosis and therapy]. Hautarzt 2012; 63: 381-389
    CrossrefPubMedSuche in Google Scholar
  • 21 Wormser GP, Dattwyler RJ, Shapiro ED et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1089-1134
    CrossrefPubMedSuche in Google Scholar
  • 22 Steere AC, Sikand VK. The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med 2003; 348: 2472-2474
    CrossrefPubMedSuche in Google Scholar
  • 23 Fingerle V, Huppertz HI. [Lyme borreliosis in children. Epidemiology, diagnosis, clinical treatment, and therapy]. Hautarzt 2007; 58: 541-550 quiz 551 – 552
    CrossrefPubMedSuche in Google Scholar
  • 24 Chodynicka B, Flisiak I, Okrasinska K et al. Lymphocytoma cutis: cases linked with Lyme disease. Cutis 2000; 66: 243-246
    PubMedSuche in Google Scholar
  • 25 Ziemer M, Eisendle K, Müller H et al. Lymphocytic infiltration of the skin (Jessner-Kanof) but not reticular erythematous mucinosis occasionally represent clinical manifestations of borrelia-associated pseudolymphoma. Br J Dermatol 2009; 161: 583-590
    CrossrefPubMedSuche in Google Scholar
  • 26 Ziemer M, Eisendle K, Zelger B. New concepts on erythema annulare centrifugum: a clinical reaction pattern that does not represent a specific clinicopathological entity. Br J Dermatol 2009; 160: 119-126
    CrossrefPubMedSuche in Google Scholar
  • 27 Nadelman RB, Nowakowski J, Forseter G et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996; 100: 502-508
    CrossrefPubMedSuche in Google Scholar
  • 28 Deluca J, Eisendle K, Zelger B. Cutaneous and systemic Lyme disease. Expert Rev Dermatol 2013; 8: 65-82
    CrossrefPubMedSuche in Google Scholar
  • 29 Asbrink E, Brehmer-Andersson E, Hovmark A. Acrodermatitis chronica atrophicans -- a spirochetosis. Clinical and histopathological picture based on 32 patients; course and relationship to erythema chronicum migrans Afzelius. Am J Dermatopathol 1986; 8: 209-219
    CrossrefPubMedSuche in Google Scholar
  • 30 Eisendle K, Zelger B. The expanding spectrum of cutaneous borreliosis. G Ital Dermatol Venereol 2009; 144: 157-171
    PubMedSuche in Google Scholar
  • 31 Aberer E, Neumann R, Stanek G. Is localised scleroderma a Borrelia infection?. Lancet 1985; 2: 278
    PubMedSuche in Google Scholar
  • 32 Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol 2000; 142: 636-644
    CrossrefPubMedSuche in Google Scholar
  • 33 Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species?. Br J Dermatol 2007; 157: 1189-1198
    CrossrefPubMedSuche in Google Scholar
  • 34 Aberer E, Stanek G. Histological evidence for spirochetal origin of morphea and lichen sclerosus et atrophicans. Am J Dermatopathol 1987; 9: 374-379
    CrossrefPubMedSuche in Google Scholar
  • 35 Fujiwara H, Fujiwara K, Hashimoto K et al. Detection of Borrelia burgdorferi DNA (B garinii or B afzelii) in morphea and lichen sclerosus et atrophicus tissues of German and Japanese but not of US patients. Arch Dermatol 1997; 133: 41-44
    CrossrefPubMedSuche in Google Scholar
  • 36 Aberer E, Schmidt BL, Breier F et al. Amplification of DNA of Borrelia burgdorferi in urine samples of patients with granuloma annulare and lichen sclerosus et atrophicus. Arch Dermatol 1999; 135: 210-212
    CrossrefPubMedSuche in Google Scholar
  • 37 Shelley WB, Shelley ED, Amurao CV. Treatment of lichen sclerosus with antibiotics. Int J Dermatol 2006; 45: 1104-1106
    CrossrefPubMedSuche in Google Scholar
  • 38 Garbe C, Stein H, Gollnick H et al. [Cutaneous B cell lymphoma in chronic Borrelia burgdorferi infection. Report of 2 cases and a review of the literature]. Hautarzt 1988; 39: 717-726
    PubMedSuche in Google Scholar
  • 39 Jelic S, Filipovic-Ljeskovic I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients; is it a fortuitous finding?. Hematol Oncol 1999; 17: 107-116
    CrossrefPubMedSuche in Google Scholar
  • 40 Steere AC, McHugh G, Damle N et al. Prospective study of serologic tests for lyme disease. Clin Infect Dis 2008; 47: 188-195
    CrossrefPubMedSuche in Google Scholar
  • 41 Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference of Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44: 590-591
    PubMedSuche in Google Scholar
  • 42 Brouqui P, Bacellar F, Baranton G et al; ESCMID Study Group on Coxiella, Anaplasma, Rickettsia and Bartonella; European Network for Surveillance of Tick-Borne Diseases. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect 2004; 10: 1108-1132
    CrossrefPubMedSuche in Google Scholar
  • 43 Sigal LH. The polymerase chain reaction assay for Borrelia burgdorferi in the diagnosis of Lyme disease. Ann Intern Med 1994; 120: 520-521
    CrossrefPubMedSuche in Google Scholar
  • 44 Coulter P, Lema C, Flayhart D et al. Two-year evaluation of Borrelia burgdorferi culture and supplemental tests for definitive diagnosis of Lyme disease. J Clin Microbiol 2005; 43: 5080-5084
    CrossrefPubMedSuche in Google Scholar
  • 45 Eisendle K, Grabner T, Zelger B. Focus floating microscopy: “gold standard” for cutaneous borreliosis?. Am J Clin Pathol 2007; 127: 213-222
    CrossrefPubMedSuche in Google Scholar
  • 46 Ljøstad U, Skogvoll E, Eikeland R et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol 2008; 7: 690-695
    CrossrefPubMedSuche in Google Scholar
  • 47 Mygland A, Ljøstad U, Fingerle V et al; European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010; 17: 8-16 e1 – 4
    CrossrefPubMedSuche in Google Scholar
  • 48 Ljostad U, Mygland A. Chronic Lyme; diagnostic and therapeutic challenges. Acta Neurol Scand Suppl 2013; 196: 38-47
    PubMedSuche in Google Scholar
  • 49 Eisendle K, Müller HG, Zelger B. Biofilms of Borrelia burgdorferi in Chronic Cutaneous Borreliosis. Am J Clin Pathol 2008; 129: 989-990
    PubMedSuche in Google Scholar
  • 50 Aberer E. What should one do in case of a tick bite?. Curr Probl Dermatol 2009; 37: 155-166
    PubMedSuche in Google Scholar